1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

13 Mar 2024
Admin
News Article

Emcure Launches OTC Portfolio of Galact for New Mothers

Emcure Pharma launches OTC portfolio with Galact supplement for breastfeeding mothers

Overview

Emcure Pharmaceuticals, an Indian pharmaceutical company with a strong focus on women’s healthcare, announces its entry into the over-the-counter (OTC) market, with their product Galact. Prescribed by healthcare professionals for more than 20 years, Galact will now also be available as an over-the-counter (OTC) offering.

Galact Ingredients & Positive Effects

Enriched with the potency of Shatavari and six other herbs, Galact is meticulously formulated to boost breast milk production for mothers. Shatavari is also known to enhance baby’s weight, sleep pattern, leading to better immunity.
While a key ingredient, Yashtimadhu, helps in enhancing cognitive function, memory, and concentration, thereby assisting in improving baby’s IQ.
Following the launch of Galact, Emcure will be able to introduce a diverse array of OTC products catering to the unique needs of women.

Words from Director: Emcure

Speaking on the occasion, Namita Thapar, whole-time director, Emcure Pharmaceuticals said, “Emcure has always focused on awareness, access, and affordability to strengthen women’s health in India. The launch of Galact marks our efforts to redefine and further elevate the standard of women’s health solutions. Our foray into the OTC segment focuses on empowering women across various life stages, starting with a portfolio tailored for their lactation journey. In India, only 64% of mothers breastfeed their babies exclusively in the first 6 months. By making Galact available over the counter, Emcure aims to sensitise all mothers to practice exclusive breastfeeding for the first 6 months in line with the WHO and UNICEF breastfeeding guidelines. Emcure plans to introduce more products under the Galact brand.”

Aims for Emcure

The company has a deep ethos of generating awareness around women’s health issues like anaemia, menstruation, and breastfeeding. With the launch of its renewed and redesigned Galact brand, Emcure aims to further the cause of breastfeeding and promote optimal nutrition for infants.

Other Proposals

Emcure Pharmaceuticals is proposing, subject to receipt of requisite approvals, market conditions and other considerations, an initial public offering of its equity shares and has filed a draft red herring prospectus dated December 16, 2023 (DRHP) with the Securities and Exchange Board of India (SEBI).
The DRHP is available on the websites of the Company at www.emcure.com, SEBI at www.sebi.gov.in, the book running lead managers, Kotak Mahindra Capital Company Limited, Axis Capital Limited, Jefferies India Private Limited, and JP Morgan India Private Limited at https://investmentbank.kotak.com, www.axiscapital.co.in, www.jefferies.com and www.jpmipl.com, respectively, and the stock exchange(s) at www.nseindia.com and www.bseindia.com, respectively.

Investments

Investors should note that investment in equity shares involves a high degree of risk and for details refer to the Red Herring Prospectus, including the section titled "Risk Factors"" of the Red Herring Prospectus when available. Potential investors should not rely on the DRHP for making any investment decision."

About Emcure Pharmaceuticals

Emcure Pharmaceuticals (EPL) is an Indian pharmaceutical company headquartered in Pune engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. Established in 1981, EPL is ranked as the 13th largest pharma company in India in terms of domestic sales for MAT September 2023.